3 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
Can administration of scopolaminebutyl from the start of the dying phase prevent death rattle during the dying phase?
Approved WMOCompleted
To gain insight into the full spectrum of temperature-induced changes in glucose homeostasis, the present study will be aimed at assessing the effect of acute whole-body heat exposure on liver insulin sensitivity, substrate oxidation and plasma…